{"id":27652,"date":"2025-07-15T14:40:11","date_gmt":"2025-07-15T21:40:11","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=27652"},"modified":"2025-07-15T14:40:13","modified_gmt":"2025-07-15T21:40:13","slug":"ivig-for-toxic-epidermal-necrolysis-ten","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/","title":{"rendered":"IgIV para la necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET)"},"content":{"rendered":"<p>La necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET) es una afecci\u00f3n cut\u00e1nea poco frecuente, pero grave, que puede ser mortal. En Estados Unidos, afecta a aproximadamente... <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574530\/\">1,9 adultos por mill\u00f3n de personas<\/a> Cada a\u00f1o. Esta afecci\u00f3n suele desarrollarse como una reacci\u00f3n al\u00e9rgica grave a ciertos medicamentos, lo que provoca erupciones, llagas y ampollas en la piel, que luego se descaman, de forma similar a lo que ocurre con las quemaduras graves.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-e049721878ff92f9bb07f55a6bd6ee04\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\t\u00bfPuede ayudar la IgIV?\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tInformaci\u00f3n gratuita sobre el tratamiento con IgIV\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">M\u00e1s informaci\u00f3n<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\">Inmunoglobulina intravenosa (IVIG)<\/a> se considera un <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5130247\/\">tratamiento potencial para la necr\u00f3lisis epid\u00e9rmica t\u00f3xica<\/a> debido a su capacidad para suprimir las reacciones de hipersensibilidad de tipo IV e inhibir la muerte celular. De hecho, un <a href=\"https:\/\/journals.lww.com\/anti-cancerdrugs\/fulltext\/2022\/01000\/intravenous_immunoglobulin_efficacy_on.96.aspx\">informe de caso reciente<\/a> Demostraron que la terapia con IgIV combinada con una terapia con esteroides en dosis altas condujo a la resoluci\u00f3n completa de la TEN inducida por pembrolizumab en un paciente.&nbsp;<\/p>\n\n\n\n<p>En este art\u00edculo, explicaremos qu\u00e9 es TEN, c\u00f3mo funciona la IgIV y c\u00f3mo ayuda a los pacientes a recuperarse de esta afecci\u00f3n cut\u00e1nea potencialmente mortal.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#Toxic_Epidermal_Necrolysis_TEN_Overview\" >Necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET): descripci\u00f3n general<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#What_Causes_Toxic_Epidermal_Necrolysis_TEN\" >\u00bfQu\u00e9 causa la necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET)?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#Efficacy_of_IVIG_Therapy_in_Toxic_Epidermal_Necrolysis_Clinical_Evidence\" >Eficacia de la terapia con IgIV en la necr\u00f3lisis epid\u00e9rmica t\u00f3xica: evidencia cl\u00ednica<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#How_IVIG_Works_in_Toxic_Epidermal_Necrolysis\" >C\u00f3mo funciona la IgIV en la necr\u00f3lisis epid\u00e9rmica t\u00f3xica<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#1_Blocking_Fas-FasL_Mediated_Apoptosis\" >1. Bloqueo de la apoptosis mediada por Fas-FasL<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#2_Reducing_Cytotoxic_T_Cell_and_NK_Cell_Activity\" >2. Reducci\u00f3n de la actividad de las c\u00e9lulas T citot\u00f3xicas y de las c\u00e9lulas NK<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#3_Anti-Inflammatory_Effects\" >3. Efectos antiinflamatorios<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#4_Modulation_of_Fc_Receptors\" >4. Modulaci\u00f3n de los receptores Fc<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#5_It_Provides_Passive_Immunity\" >5. Proporciona inmunidad pasiva<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#When_and_How_Long_Is_IVIG_Therapy_Given_to_TEN_Patients\" >\u00bfCu\u00e1ndo y durante cu\u00e1nto tiempo se administra la terapia con IgIV a los pacientes con TEN?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#Are_There_Any_Side_Effects_of_IVIG\" >\u00bfExisten efectos secundarios de la IgIV?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#How_Does_Toxic_Epidermal_Necrolysis_Differ_From_SJS\" >\u00bfEn qu\u00e9 se diferencia la necr\u00f3lisis epid\u00e9rmica t\u00f3xica del s\u00edndrome de Stevens-Johnson?<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-toxic-epidermal-necrolysis-ten-overview\"><span class=\"ez-toc-section\" id=\"Toxic_Epidermal_Necrolysis_TEN_Overview\"><\/span><strong>Necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET): descripci\u00f3n general<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La necr\u00f3lisis epid\u00e9rmica t\u00f3xica, tambi\u00e9n conocida como s\u00edndrome de Lyell, es una forma rara y muy grave del s\u00edndrome de Stevens-Johnson (SSJ). En personas con SSJ, la NET se diagnostica cuando se afecta m\u00e1s de 30% de la superficie cut\u00e1nea y se produce un da\u00f1o extenso en las membranas mucosas, que son las capas h\u00famedas del cuerpo.&nbsp;<\/p>\n\n\n\n<p>Al igual que el SSJ, la afecci\u00f3n suele comenzar con s\u00edntomas gripales que aparecen de 1 a 3 semanas despu\u00e9s de comenzar a tomar un medicamento. Posteriormente, se presenta una erupci\u00f3n cut\u00e1nea dolorosa, de color rojo o viol\u00e1ceo, que se extiende r\u00e1pidamente a la cara, el cuello, el tronco y el resto del cuerpo de forma irregular. Se forman ampollas y grandes porciones de piel pueden desprenderse, dejando expuestas zonas en carne viva llamadas erosiones, similares a una quemadura grave por agua caliente.<\/p>\n\n\n\n<p>El da\u00f1o generalizado a la piel y las membranas mucosas, como la boca, la nariz, la garganta y los genitales, puede causar p\u00e9rdida grave de l\u00edquidos e infecci\u00f3n. En los casos m\u00e1s graves, los pacientes pueden experimentar shock, sepsis, insuficiencia multiorg\u00e1nica y la muerte.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-causes-toxic-epidermal-necrolysis-ten\"><span class=\"ez-toc-section\" id=\"What_Causes_Toxic_Epidermal_Necrolysis_TEN\"><\/span><strong>\u00bfQu\u00e9 causa la necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET)?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La TEN se desencadena por un medicamento espec\u00edfico (p. ej., antibi\u00f3ticos, anticonvulsivos, antigotosos, AINE). Cuando el sistema inmunitario reacciona de forma exagerada a ciertos medicamentos, ataca por error la piel y las mucosas. Esta reacci\u00f3n es una alergia retardada (reacci\u00f3n de hipersensibilidad tipo IV) en la que intervienen c\u00e9lulas inmunitarias especiales llamadas linfocitos T citot\u00f3xicos y linfocitos citol\u00edticos naturales (NK).<\/p>\n\n\n\n<p>Cuando estas c\u00e9lulas se activan, liberan sustancias (granulisina, perforina y granzima) que da\u00f1an la capa externa de la piel (epidermis), provocando su muerte y descamaci\u00f3n. Una parte crucial de este da\u00f1o proviene de una se\u00f1al llamada <strong><em>Ligando Fas<\/em><\/strong>, que indica a las c\u00e9lulas de la piel (queratinocitos) que se autodestruyan.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-efficacy-of-ivig-therapy-in-toxic-epidermal-necrolysis-clinical-evidence\"><span class=\"ez-toc-section\" id=\"Efficacy_of_IVIG_Therapy_in_Toxic_Epidermal_Necrolysis_Clinical_Evidence\"><\/span><strong>Eficacia de la terapia con IgIV en la necr\u00f3lisis epid\u00e9rmica t\u00f3xica: evidencia cl\u00ednica<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los estudios sobre la eficacia de la IgIV en la NET son limitados debido a la rareza de la enfermedad. Sin embargo, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2958184\/\">informes de casos m\u00faltiples<\/a>Estudios prospectivos abiertos y series de casos retrospectivos han demostrado resultados positivos de la terapia con IgIV en pacientes con TEN si se inicia de manera temprana.&nbsp;<\/p>\n\n\n\n<p>Por ejemplo, una <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2020\/6274053\">informe de caso<\/a> El tratamiento con IgIV y la atenci\u00f3n en la unidad pedi\u00e1trica de quemados de un ni\u00f1o de 5 a\u00f1os con NET inducida por lamotrigina tuvo excelentes resultados.<strong>,<\/strong> con una curaci\u00f3n m\u00e1s r\u00e1pida y un menor riesgo de mortalidad que cualquiera de los tratamientos por separado.&nbsp;<\/p>\n\n\n\n<p>De manera similar, otro <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39871376\/\">informe de caso<\/a> El estudio de un hombre de 83 a\u00f1os con NET que recibi\u00f3 IgIV (400 mg\/kg\/d\u00eda durante 5 d\u00edas) tras una respuesta insuficiente a esteroides en dosis altas mostr\u00f3 una mejor\u00eda de los s\u00edntomas cut\u00e1neos. Sin embargo, el paciente desarroll\u00f3 trombocitopenia.<strong> <\/strong>(bajo recuento de plaquetas), que se resolvi\u00f3 despu\u00e9s del tratamiento con IgIV.&nbsp;<\/p>\n\n\n\n<p>Aunque la IgIV muestra resultados prometedores, requiere un seguimiento cuidadoso para detectar posibles efectos adversos.<\/p>\n\n\n\n<div  id=\"call-to-action-df30ebb5f13dc5872c6d25dd50ebaee0\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tConsulte a un especialista en IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-ivig-works-in-toxic-epidermal-necrolysis\"><span class=\"ez-toc-section\" id=\"How_IVIG_Works_in_Toxic_Epidermal_Necrolysis\"><\/span><strong>C\u00f3mo funciona la IgIV en la necr\u00f3lisis epid\u00e9rmica t\u00f3xica<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient.jpg\" alt=\"IVIG nurse with patient\" class=\"wp-image-27654\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-18x12.jpg 18w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-nurse-patient-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>El mecanismo de acci\u00f3n de la IgIV es complejo y no se comprende completamente. Sin embargo, las investigaciones han demostrado que la IgIV modula la respuesta inmunitaria al inhibir o bloquear v\u00edas inmunomediadas espec\u00edficas.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-1-blocking-fas-fasl-mediated-apoptosis\"><span class=\"ez-toc-section\" id=\"1_Blocking_Fas-FasL_Mediated_Apoptosis\"><\/span>1. Bloqueo de la apoptosis mediada por Fas-FasL<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>En pacientes con TEN, la v\u00eda Fas-Fas Ligando (FasL) es un mecanismo central que causa desprendimiento masivo de piel y formaci\u00f3n de ampollas.<strong>.<\/strong> Los queratinocitos (c\u00e9lulas cut\u00e1neas) poseen receptores Fas en su superficie, que pueden unirse a los ligandos Fas (FasL) liberados por las c\u00e9lulas inmunitarias. La uni\u00f3n Fas-FasL desencadena la apoptosis (muerte celular programada) de las c\u00e9lulas cut\u00e1neas.&nbsp;<\/p>\n\n\n\n<p>La inmunoglobulina anti-Fas presente en <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2958184\/\">La IgIV bloquea el receptor Fas<\/a> uni\u00e9ndose a \u00e9l, evitando as\u00ed que FasL se adhiera a sus receptores en las c\u00e9lulas de la piel.<strong> <\/strong>Esta interrupci\u00f3n en la interacci\u00f3n Fas-FasL detiene la apoptosis, retardando o deteniendo la muerte de m\u00e1s c\u00e9lulas de la piel.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2-reducing-cytotoxic-t-cell-and-nk-cell-activity\"><span class=\"ez-toc-section\" id=\"2_Reducing_Cytotoxic_T_Cell_and_NK_Cell_Activity\"><\/span>2. <strong>Reducci\u00f3n de la actividad de las c\u00e9lulas T citot\u00f3xicas y de las c\u00e9lulas NK<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La IgIV modula la respuesta inmunitaria mediante <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5130247\/\">regulaci\u00f3n negativa de la funci\u00f3n de las c\u00e9lulas T citot\u00f3xicas hiperactivas y de las c\u00e9lulas NK<\/a>Esto reduce la liberaci\u00f3n de otras mol\u00e9culas da\u00f1inas (como la granulisina y la granzima B) que contribuyen al da\u00f1o tisular.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-3-anti-inflammatory-effects\"><span class=\"ez-toc-section\" id=\"3_Anti-Inflammatory_Effects\"><\/span>3. Efectos antiinflamatorios<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La IgIV produce efectos antiinflamatorios que ayudan a neutralizar los efectos de las citocinas proinflamatorias.<strong> <\/strong>como<strong> <\/strong>TNF-\u03b1, IL-2 e IFN-\u03b3, que est\u00e1n elevados en TEN y contribuyen a la inflamaci\u00f3n y la lesi\u00f3n tisular.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-4-modulation-of-fc-receptors\"><span class=\"ez-toc-section\" id=\"4_Modulation_of_Fc_Receptors\"><\/span>4. Modulaci\u00f3n de los receptores Fc<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El receptor Fc desempe\u00f1a un papel en la activaci\u00f3n inmunitaria. Los anticuerpos IgIV se unen a los receptores Fc presentes en las c\u00e9lulas inmunoactivadoras, como los macr\u00f3fagos y las c\u00e9lulas dendr\u00edticas, lo que... <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5130247\/\">interfiriendo con la activaci\u00f3n celular y la presentaci\u00f3n de ant\u00edgenos<\/a>Esto evita una mayor activaci\u00f3n inmune y el reclutamiento de c\u00e9lulas inmunes adicionales a la piel.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-5-it-provides-passive-immunity\"><span class=\"ez-toc-section\" id=\"5_It_Provides_Passive_Immunity\"><\/span>5. <strong>Proporciona inmunidad pasiva<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Aunque no es su objetivo principal en la TEN, la IgIV tambi\u00e9n aumenta los niveles generales de anticuerpos del paciente y ofrece protecci\u00f3n contra infecciones secundarias en la TEN debido a la p\u00e9rdida de piel.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-when-and-how-long-is-ivig-therapy-given-to-ten-patients\"><span class=\"ez-toc-section\" id=\"When_and_How_Long_Is_IVIG_Therapy_Given_to_TEN_Patients\"><\/span><strong>\u00bfCu\u00e1ndo y durante cu\u00e1nto tiempo se administra la terapia con IgIV a los pacientes con TEN?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La IgIV se inicia lo antes posible, preferiblemente dentro de las 24 horas posteriores al diagn\u00f3stico. La duraci\u00f3n del tratamiento con IgIV puede variar seg\u00fan la gravedad de la enfermedad. Normalmente, en casos de necr\u00f3lisis epid\u00e9rmica t\u00f3xica, los pacientes reciben infusiones diarias de IgIV durante 3 a 5 d\u00edas.<\/p>\n\n\n\n<p>Puede recibir una dosis inicial de IgIV, hasta <a href=\"https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2481\">3 g\/kg, divididos en 3 d\u00edas<\/a> (1 g\/kg\/d\u00eda) o hasta 2 g\/kg administrados en dosis \u00fanica.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-are-there-any-side-effects-of-ivig-nbsp\"><span class=\"ez-toc-section\" id=\"Are_There_Any_Side_Effects_of_IVIG\"><\/span><strong>\u00bfExisten efectos secundarios de la IgIV?&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Un paciente con necr\u00f3lisis epid\u00e9rmica t\u00f3xica puede experimentar efectos secundarios como n\u00e1useas, dolor de cabeza, escalofr\u00edos o fiebre mientras recibe la infusi\u00f3n. En casos raros, puede presentarse trombocitopenia (bajo recuento de plaquetas) o meningitis as\u00e9ptica, lo que requiere una monitorizaci\u00f3n cuidadosa.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-5f863a325016c34f11036dbec9f52a4b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga autorizaci\u00f3n previa para IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Empezar<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-does-toxic-epidermal-necrolysis-differ-from-sjs\"><span class=\"ez-toc-section\" id=\"How_Does_Toxic_Epidermal_Necrolysis_Differ_From_SJS\"><\/span><strong>\u00bfEn qu\u00e9 se diferencia la necr\u00f3lisis epid\u00e9rmica t\u00f3xica del s\u00edndrome de Stevens-Johnson?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Aunque tanto el SJS como la TEN implican descamaci\u00f3n de la piel y da\u00f1o a las membranas mucosas, difieren en el grado de afectaci\u00f3n corporal.&nbsp;<\/p>\n\n\n\n<p>Si la superficie corporal afectada es inferior a 10%, se diagnostica SSJ. Si la superficie corporal afectada es superior a 30%, se diagnostica NET. Los casos que afectan entre 10 y 30% se clasifican en la categor\u00eda de superposici\u00f3n (SSJ\/NET).<\/p>","protected":false},"excerpt":{"rendered":"<p>La necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET) es una afecci\u00f3n cut\u00e1nea poco frecuente, pero grave, que puede ser mortal. En Estados Unidos, afecta a aproximadamente 1,9 adultos por mill\u00f3n de personas cada a\u00f1o. Esta afecci\u00f3n suele desarrollarse como una reacci\u00f3n al\u00e9rgica grave a ciertos medicamentos, lo que provoca la aparici\u00f3n de erupciones, llagas y ampollas en la piel, seguidas de descamaci\u00f3n, similar a lo que ocurre con las quemaduras graves.\u00a0<\/p>","protected":false},"author":27,"featured_media":27656,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[33],"class_list":["post-27652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-samantha-kaeberlein"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Toxic Epidermal Necrolysis (TEN) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Learn how IVIG can be used to treat toxic epidermal necrolysis. Topics include how IVIG works, efficacy, side effects, and more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Toxic Epidermal Necrolysis (TEN) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Learn how IVIG can be used to treat toxic epidermal necrolysis. Topics include how IVIG works, efficacy, side effects, and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T21:40:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T21:40:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Samantha Kaeberlein, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Samantha Kaeberlein, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/\"},\"author\":{\"name\":\"Dr. Samantha Kaeberlein, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/aa941bb470287e10309b2fe7f5b15430\"},\"headline\":\"IVIG for Toxic Epidermal Necrolysis (TEN)\",\"datePublished\":\"2025-07-15T21:40:11+00:00\",\"dateModified\":\"2025-07-15T21:40:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/\"},\"wordCount\":1059,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/IVIG-for-TEN.jpg\",\"keywords\":[\"Dr. Samantha Kaeberlein\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/\",\"name\":\"IVIG for Toxic Epidermal Necrolysis (TEN) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/IVIG-for-TEN.jpg\",\"datePublished\":\"2025-07-15T21:40:11+00:00\",\"dateModified\":\"2025-07-15T21:40:13+00:00\",\"description\":\"Learn how IVIG can be used to treat toxic epidermal necrolysis. Topics include how IVIG works, efficacy, side effects, and more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/IVIG-for-TEN.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/IVIG-for-TEN.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Nurse setting up IVIG for patient with toxic epidermal necrolysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-toxic-epidermal-necrolysis-ten\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Toxic Epidermal Necrolysis (TEN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/aa941bb470287e10309b2fe7f5b15430\",\"name\":\"Dr. Samantha Kaeberlein, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g\",\"caption\":\"Dr. Samantha Kaeberlein, PharmD\"},\"description\":\"Dr. Samantha Kaeberlein, PharmD was born and raised in Canton, OH. She received her pharmacy degree from Northeast Ohio Medical University (NEOMED) in 2020. The most rewarding part of her job is providing medical guidance so patients can make informed, well-rounded decisions regarding their healthcare. Her areas of expertise are geriatrics and long-term care. In her free time, she enjoys spending time outdoors, reading, and hunting for the best cup of coffee in America.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/samantha\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Aprenda c\u00f3mo se puede usar la IgIV para tratar la necr\u00f3lisis epid\u00e9rmica t\u00f3xica. Los temas incluyen c\u00f3mo funciona la IgIV, su eficacia, sus efectos secundarios y m\u00e1s.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for Toxic Epidermal Necrolysis (TEN) - AmeriPharma\u00ae Specialty Care","og_description":"Learn how IVIG can be used to treat toxic epidermal necrolysis. Topics include how IVIG works, efficacy, side effects, and more.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2025-07-15T21:40:11+00:00","article_modified_time":"2025-07-15T21:40:13+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg","type":"image\/jpeg"}],"author":"Dr. Samantha Kaeberlein, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Samantha Kaeberlein, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/"},"author":{"name":"Dr. Samantha Kaeberlein, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/aa941bb470287e10309b2fe7f5b15430"},"headline":"IVIG for Toxic Epidermal Necrolysis (TEN)","datePublished":"2025-07-15T21:40:11+00:00","dateModified":"2025-07-15T21:40:13+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/"},"wordCount":1059,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg","keywords":["Dr. Samantha Kaeberlein"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/","name":"IgIV para la necr\u00f3lisis epid\u00e9rmica t\u00f3xica (NET) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg","datePublished":"2025-07-15T21:40:11+00:00","dateModified":"2025-07-15T21:40:13+00:00","description":"Aprenda c\u00f3mo se puede usar la IgIV para tratar la necr\u00f3lisis epid\u00e9rmica t\u00f3xica. Los temas incluyen c\u00f3mo funciona la IgIV, su eficacia, sus efectos secundarios y m\u00e1s.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg","width":1280,"height":853,"caption":"Nurse setting up IVIG for patient with toxic epidermal necrolysis"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-toxic-epidermal-necrolysis-ten\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for Toxic Epidermal Necrolysis (TEN)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/aa941bb470287e10309b2fe7f5b15430","name":"Dra. Samantha Kaeberlein, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fabe5720eac93901a4790d5e25493a8cf2fdf076c21466237b10de4cc181b9d2?s=96&d=mm&r=g","caption":"Dr. Samantha Kaeberlein, PharmD"},"description":"La Dra. Samantha Kaeberlein, PharmD, naci\u00f3 y creci\u00f3 en Canton, Ohio. Obtuvo su t\u00edtulo en farmacia en la Universidad M\u00e9dica del Noreste de Ohio (NEOMED) en 2020. Lo m\u00e1s gratificante de su trabajo es brindar orientaci\u00f3n m\u00e9dica para que los pacientes puedan tomar decisiones informadas y completas sobre su atenci\u00f3n m\u00e9dica. Sus \u00e1reas de especializaci\u00f3n son la geriatr\u00eda y los cuidados a largo plazo. En su tiempo libre, disfruta de pasar tiempo al aire libre, leer y encontrar el mejor caf\u00e9 de Estados Unidos.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/samantha\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Samantha Kaeberlein, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/samantha\/"},"uagb_comment_info":0,"uagb_excerpt":"Toxic epidermal necrolysis (TEN) is a rare but serious skin condition that can be life-threatening. In the United States, it affects about 1.9 adults per million people each year. This condition typically develops as a severe allergic reaction to certain medications, causing your skin to develop rashes, sores, and blisters, then peel, similar to what&hellip;","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/07\/IVIG-for-TEN.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Samantha Kaeberlein, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/samantha\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Toxic epidermal necrolysis (TEN) is a rare but serious skin condition that can be life-threatening. In the United States, it affects about 1.9 adults per million people each year. This condition typically develops as a severe allergic reaction to certain medications, causing your skin to develop rashes, sores, and blisters, then peel, similar to what&hellip;","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27652"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27652\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27656"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27652"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}